KR850004390A - 아미노산 용액의 제조방법 - Google Patents

아미노산 용액의 제조방법 Download PDF

Info

Publication number
KR850004390A
KR850004390A KR1019840008115A KR840008115A KR850004390A KR 850004390 A KR850004390 A KR 850004390A KR 1019840008115 A KR1019840008115 A KR 1019840008115A KR 840008115 A KR840008115 A KR 840008115A KR 850004390 A KR850004390 A KR 850004390A
Authority
KR
South Korea
Prior art keywords
amino acid
weight
solution
acid solution
mixed
Prior art date
Application number
KR1019840008115A
Other languages
English (en)
Inventor
리고 작크
Original Assignee
에. 뚜레 레메뜨르
신 떼라보
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9295350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850004390(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에. 뚜레 레메뜨르, 신 떼라보 filed Critical 에. 뚜레 레메뜨르
Publication of KR850004390A publication Critical patent/KR850004390A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

아미노산 용액의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 필수아미노산인 L―트레오닌, L―류신, L―이소류신, L―발린, L―메티오닌, L―페닐일라닌, L―트립토판, L―리신 및 L―히스티단과, 반―필수아미노산인 L-씨스테인, 타우린 및 L-티토신과, 기타 아미노산을 46 내지 63중량%의 총 아미노산이 필수아미노산 및 반―필수아미노산인 용액을 얻게하는 비율로 용액내에서 혼합시키는 것을 특징으로 하는, 저―출생체중의 만기신생아나 어린 유아에게 경구적으로, 장내에 또는 비경구적으로 투여할 아미노산 용액을 제조하는 방법.
  2. 제1항에 있어서, 사용된 아미노산의 20.4 내지 27.7중량%의 측쇄아미노산과, 6.0 내지 8.1중량%의 방향족 아미노산과, 2.0 내지 2.7중량%의 메티오닌과, 1.6 내지 2.2중량%의 씨스테인과, 0.5 내지 0.7중량%의 타우린과 1.9 내지 2.6중량%의 오르니틴으로 구성되는 것을 특징으로 하는 아미노산 용액의 제조방법.
  3. 제1항 또는 제2항에 있어서, 단당류, 전해질, 광물질, 흔적성원소, 비타민 그리고/또는 지질도 역시 사용되는 것을 특징으로 하는 아미노산용액의 제조방법.
  4. 제1항 내지 제2항중 어느 하나에 있어서, 아미노산의 농도가 2 내지 10g/100ml의 용액인 것을 특징으로 하는 아미노산 용액의 제조방법.
  5. 제1항 내지 제4항중 어느 하나에 있어서, 아미노산의 총 중량을 기준으로, 다음과 같은 중량 백분율의 아미노산을 혼합하는 것을 특징으로 하는, 아미노산 용액의 제조방법.
  6. 제1항 내지 제5항중 어느 하나에 있어서, 용액 100ml당의 mg으로 표시한 다음의 성분을 혼합하여 용액을 형성하는 것을 특징으로 하는, 아미노산 용액의 제조방법.
  7. 제3항에 있어서, 제6항에 기재한 아미노산의 양을 적당한 전해질, 광물질 및 흔적성원소와 혼합하여 100ml당 다음의 것을 함유하는 용액을 얻는 것을 특징으로 하는, 아미노산 용액의 제조방법.
  8. 제3항에 있어서, 20% 농도의 단당류 용액 2용량부를 청구범위 7항의 아미노산 용액 1용량부와 혼합시키는 것을 특징으로 하는 아미노산 용액의 제조방법.
  9. 제3항에 있어서, 30% 농도인 글루코즈 용액 4용량부와, 20% 농도인 지질유제 1용량부와, 청구범위 6항의 아미노산 용액 6용량부를 혼합하는 것을 특징으로 하는 아미노산 용액의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840008115A 1983-12-20 1984-12-19 아미노산 용액의 제조방법 KR850004390A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8320383A FR2556594B1 (fr) 1983-12-20 1983-12-20 Solutions d'acides amines
FR83-20383 1983-12-20

Publications (1)

Publication Number Publication Date
KR850004390A true KR850004390A (ko) 1985-07-15

Family

ID=9295350

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840008115A KR850004390A (ko) 1983-12-20 1984-12-19 아미노산 용액의 제조방법

Country Status (16)

Country Link
EP (1) EP0148680B1 (ko)
JP (1) JPS60166612A (ko)
KR (1) KR850004390A (ko)
AT (1) ATE38331T1 (ko)
AU (1) AU565840B2 (ko)
CA (1) CA1235598A (ko)
DE (1) DE3474914D1 (ko)
DK (1) DK611184A (ko)
FR (1) FR2556594B1 (ko)
GR (1) GR82510B (ko)
IL (1) IL73871A0 (ko)
MA (1) MA20304A1 (ko)
NZ (1) NZ210638A (ko)
OA (1) OA07905A (ko)
PT (1) PT79713B (ko)
ZA (1) ZA849906B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583852D1 (de) * 1984-11-19 1991-09-26 Montefiore Hospital Ass Of Wes Naehrstoffzusammensetzungen.
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FR2605854B1 (fr) * 1986-10-30 1990-07-06 Futur Quotidien Sa Complement dietetique a des fins energetiques
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
FI904074A0 (fi) * 1989-08-28 1990-08-17 Milupa Ag Protein-, peptid- och aminosyrablandningar med optimerad aminosyrasammansaettning samt deras anvaendning foer framstaellning av naering foer prematur- och dibarn samt av tillsatser till modersmjoelk.
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
CN1110112A (zh) * 1994-04-11 1995-10-18 贾增申 一种氨基酸固体饮料及其制备方法
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
ES2767600T3 (es) * 2012-11-23 2020-06-18 Nutricia Nv Fórmulas que comprenden perfiles de aminoácidos optimizados
EP3145333B1 (en) 2014-05-19 2020-11-04 N.V. Nutricia Infant formula with optimised amino acid profiles
EP3338841A1 (en) * 2016-12-23 2018-06-27 Ferdinand Haschke Liquid human milk supplement
GB201807155D0 (en) * 2018-05-01 2018-06-13 Liverpool Womens Trust Nhs Found Trust Neonatal Parenteral nutrition formulations
JP2022045047A (ja) * 2020-09-08 2022-03-18 デンカ株式会社 偽陰性の抑制により特異性を改善した検査試薬
JP2022045189A (ja) * 2020-09-08 2022-03-18 デンカ株式会社 偽陽性の抑制により特異性を改善した検査キット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950529A (en) * 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use

Also Published As

Publication number Publication date
MA20304A1 (fr) 1985-07-01
ATE38331T1 (de) 1988-11-15
OA07905A (fr) 1986-11-20
ZA849906B (en) 1985-08-28
FR2556594A1 (fr) 1985-06-21
CA1235598A (en) 1988-04-26
EP0148680A1 (fr) 1985-07-17
FR2556594B1 (fr) 1988-09-09
PT79713A (fr) 1985-01-01
DK611184D0 (da) 1984-12-19
PT79713B (fr) 1986-12-30
AU565840B2 (en) 1987-10-01
AU3691284A (en) 1985-07-04
DK611184A (da) 1985-06-21
DE3474914D1 (en) 1988-12-08
NZ210638A (en) 1987-05-29
JPS60166612A (ja) 1985-08-29
EP0148680B1 (fr) 1988-11-02
IL73871A0 (en) 1985-03-31
GR82510B (en) 1985-04-22

Similar Documents

Publication Publication Date Title
KR850004390A (ko) 아미노산 용액의 제조방법
Jahoor et al. Protein-deficient pigs cannot maintain reduced glutathione homeostasis when subjected to the stress of inflammation
Wykes et al. Chronic low protein intake reduces tissue protein synthesis in a pig model of protein malnutrition
Richie Jr et al. Tissue glutathione and cysteine levels in methionine-restricted rats
Oldendorf Saturation of blood brain barrier transport of amino acids in phenylketonuria
US3849554A (en) Reduction of blood serum cholesterol
KR910000140A (ko) 신장 질환 치료용 영양제제
ATE49855T1 (de) Diaetetischer zusatz zur beeinflussung des schlafes.
Rodrı́guez et al. The increased skeletal muscle protein turnover of the streptozotozin diabetic rat is associated with high concentrations of branched-chain amino acids
KR920007571A (ko) 영양학적 조성물 및 이의 제조방법
Mashio et al. Synaptosomal T3 binding sites in rat brain: their localization on synaptic membrane and regional distribution
Philbrick et al. Development of malnutrition in rats
Vorhees et al. Progress in experimental phenylketonuria: a critical review
Heubi et al. Postnatal development of intestinal bile salt transport. Relationship to membrane physico-chemical changes.
Sturman et al. Cystine metabolism in vitamin B6 deficiency: Evidence of muliple taurine pools
Grimble Sulphur amino acids, glutathione and immune function.
Wapnir et al. Oral hydration solutions in experimental osmotic diarrhea: enhancement by alanine and other amino acids and oligopeptides
DE68910126T2 (de) Nahrungsmittelzusammensetzung.
CA3165947A1 (en) Sleep dietary supplement
Leguina-Ruzzi et al. Glutamine: a conditionally essential amino acid with multiple biological functions
GLASS et al. Decreased serum 3, 5, 3′-triiodothyronine (T3) and abnormal serum binding of T3 in calorie-deficient rats: Adaptation after chronic underfeeding
Murlin et al. Biological Value of Proteins in Relation to the Essential Amino Acids Which They Contain: III. Comparison of Proteins with Mixtures of the Amino Acids
Kreutler et al. Interactions of protein deficiency, cyanide, and thiocyanate on thyroid function in neonatal and adult rats
Nasset et al. Nitrogen balance index in the adult rat as affected by diets low in L-and DL-methionine
Govinatzki et al. Amino acid metabolism in rat hippocampus during the period of brain growth spurt

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application